260968-87-4Relevant academic research and scientific papers
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway
Castanedo, Georgette M.,Wang, Shumei,Robarge, Kirk D.,Blackwood, Elizabeth,Burdick, Daniel,Chang, Christine,Dijkgraaf, Gerrit J.P.,Gould, Stephen,Gunzner, Janet,Guichert, Oivin,Halladay, Jason,Khojasteh, Cyrus,Lee, Leslie,Marsters Jr., James C.,Murray, Lesley,Peterson, David,Plise, Emile,Salphati, Laurent,De Sauvage, Frederic J.,Wong, Susan,Sutherlin, Daniel P.
scheme or table, p. 6748 - 6753 (2011/01/12)
Potent and efficacious inhibitors of the hedgehog pathway for the treatment of cancer have been prepared using the 2-pyridyl biphenyl amide scaffold common to the clinical lead GDC-0449. Analogs with polar groups in the para-position of the aryl amide ring optimized potency, had minimal CYP inhibition, and possessed good exposure in rats. Compounds 9d and 14f potently inhibited hedgehog signaling as measured by Gli1 mRNA and were found to be equivalent or more potent than GDC-0449, respectively, when studied in a Ptch+/- medulloblastoma allograft model, that is, highly dependent on hedgehog signaling.
PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING
-
Page/Page column 192, (2009/11/29)
The invention provides novel inhibitors of hedgehog signaling that are useful as s therapeutic agent for treating malignancies where the compounds have the general formula (I): where A, X, Y R1, R2, R3, R4, m and n are as described herein.
Pyridyl inhibitors of hedgehog signalling
-
Page/Page column 125-126, (2010/10/20)
The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
COMPOUNDS USEFUL AS AICARFT INHIBITORS
-
, (2008/06/13)
Compounds of the formula:(where R1, R2 and R3 are defined in the specification) are inhibitors of AICARFT. These compounds, as well as their pharmaceutically acceptable salts, solvents, prodrugs, and pharmaceutically active metabolites, are useful in pharmaceutical compositions for treating diseases such as cancer.
